通道阻塞剂和β阻塞剂组合对读取到读取血压变异性的影响:一个随机交叉试验
Jia-Hui Xia1, Yi-Bang Cheng, Ting-Yan Xu
1Department of Cardiovascular Medicine, Centre for Epidemiological Studies and Clinical Trials, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, National Research Centre for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Blood pressure monitoring
|January 20, 2025
概括
尼二平/阿提诺洛尔组合有效降低了血压和白天血压变化. 然而,它并没有证明在高血压管理方面优于单独的尼二平或阿提诺洛尔治疗方法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压管理通常涉及组合疗法,以实现最佳的血压控制.
- 血压变化 (BPV) 是心血管事件的新兴风险因素.
- 使用门诊血压监测 (ABPM) 评估BPV为治疗疗效提供了宝贵的见解.
研究的目的:
- 为了比较尼二平/阿提诺洛尔组合与单一治疗的疗效,使用两种药物的标准剂量.
- 评估这些治疗对血压 (BP) 和血压变化 (BPV) 的影响.
- 通过门诊血压监测来评估BP和BPV.
主要方法:
- 一项随机交叉试验,涉及32名1级高血压和白天高血压的患者 (30-65岁).
- 患者接受了尼二平/阿提诺洛结合剂 (10/20毫克) 或单一治疗 (尼二平10毫克或阿提诺洛25毫克) 持续6周,随后进行交叉治疗.
- 门诊血压监测用于评估BP和BPV.
主要成果:
- 尼丁平/阿提诺洛尔组合显著降低了临床和门诊血压和脉冲比基线.
- 随着组合治疗,24小时和白天缩和腹缩BPV的显著降低.
- 在治疗结束时,组合疗法和单疗法组之间没有发现BPV的显著差异.
结论:
- 尼二平/阿提诺洛尔组合有效地减少了白天读取到读取的血压变化.
- 组合疗法在整体疗效方面没有表现出优于标准剂量尼二或阿诺洛尔单疗的优势.
- 可能需要进一步的研究,以充分阐明组合治疗在管理BPV中的作用.
相关概念视频
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
449
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
449
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
450
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
450
01:17Antihypertensive Drugs: Action of β1 Blockers
306
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
306
01:28Antihypertensive Drugs: Types of β-Blockers
573
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
573
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405